Is Eli Lilly and Co halal to invest in?

As of August 2026, Eli Lilly and Co LLYC.VI is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.

Is Eli Lilly and Co a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Eli Lilly and Co using these criteria to determine its compliance status.

Can Muslims buy shares of Eli Lilly and Co?

Muslim investors may consider investing in Eli Lilly and Co if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Eli Lilly and Co classified as HALAL?

Musaffa determines the Shariah status of Eli Lilly and Co by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Eli Lilly and Co updated?

The Shariah compliance status of Eli Lilly and Co may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Eli Lilly and Co become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Eli Lilly and Co?

You can check the latest Shariah compliance status of Eli Lilly and Co on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Eli Lilly and Co LLYC.VI

Last Updated: Aug 12, 12:00 AM·WBAG

LLYC.VI Shariah Compliance

Screening Methodology: AAOIFI

As of August 2026, Eli Lilly and Co is classified as halal.

HALAL

Report Source: undefined Quarter Report

Eli Lilly and Co. Stock Analysis LLYC.VI

Austria Health Care Mega Cap

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 50,000 full-time employees. The firm manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.